摘要
目的:探讨血清甲壳质酶蛋白40(YKL-40)、人附睾蛋白4(HE4)在上皮性卵巢肿瘤的表达及临床意义。方法:用酶联免疫吸附试验,检测健康妇女、上皮性良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌患者血清中YKL-40、HE4的水平。结果:(1)健康妇女、上皮性良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌患者术前血清中,YKL-40表达中位数分别为35.56、41.42、44.34和130.25μg/L;HE4的表达中位数分别为41.10、43.98、65.21和260.90pmol/L;在术前卵巢癌组YKL-40、HE4的表达水平均高于前3组,差异有统计学意义(P<0.05),前3组之间差异无统计学意义;卵巢癌患者术后血清中YKL-40、HE4中位数分别为58.57μg/L、124.32pmol/L,术前血清水平明显高于术后(P<0.05);(2)卵巢癌患者术前血清YKL-40浓度与FIGO分期、血清CA125浓度呈正相关(P<0.05);术前血清HE4浓度与病理类型、血清CA125浓度、年龄相关。结论:血清YKL-40、HE4有望成为卵巢癌标志物,用于早期诊断和预后分析。
Objective：To explore the expressions and signiticance ot serum YKL-40, human epididymis protein 4 （HFA）in patients with epithelial ovarian tumor. Methods：The enzyme-linked immuno-sorbent assay（ELISA）technique was applied to detect serum YKL-40 and HFA levels in healthy women and patients of benign ovarian tumor, borderline ovarian tumor, and ovarian eai＇cinoma. Results： （ 1 ） In healthy women, benign ovarian tumor, borderline ovarian tumor, preoperative ovarian carcinoma, the serum YKL-40 median levels were 35.56,41.42, 44.34,130.251μg/L respectively. The serum HE4 median levels were 41.10,43.98,65.21 and 260.90pmol/L respectively. The preoperative median levels of YKL-40, HE4 in ovarian carcinoma group were significantly higher than those of the former three groups（ P〈0.05 ）. The former three groups were further compared, no statistically significant difference was found respectively（P〉0.05）. In ovarian carcinoma group, the median postoperative YKL40, HE4 levels were 58. 57μg/L, 124.32pmol/L, the levels of preoperative were significantly higher than postoperative levels（P〈0.05 ）. （2）In ovarian carcinoma group, the preoperative serum YKL-40 Levels positively correlated with stage ,the concentration of CA125. The preoperative serum HFA levels associated with pathological types,the concentration of CA125 and patients＇age. Conclusion：Serum YKL-40, HE4 levels can be seen as biomarkers of the ovarian carcinomas.
出处
《现代妇产科进展》
CSCD
北大核心
2009年第11期847-850,共4页
Progress in Obstetrics and Gynecology
